BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Working Capital to Net Assets Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Working Capital to Net Assets ratio of 24.4% as of December 2024. Working capital of €13.09 Billion (current assets of €24.63 Billion minus current liabilities of €11.54 Billion) is measured against net assets of €53.63 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See R2WA equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
BEXIMCO PHARMA.GDR REGS 1 Working Capital to Net Assets (2021–2024)
This chart shows how BEXIMCO PHARMA.GDR REGS 1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 24.4%, reflecting working capital of €13.09 Billion against net assets of €53.63 Billion EUR. Check how tangible is BEXIMCO PHARMA.GDR REGS 1's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of BEXIMCO PHARMA.GDR REGS 1.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 21.7% | €11.26 Billion | €51.90 Billion | €20.82 Billion | €9.56 Billion | ▲ +5.7 pp |
| 2023 | 16.0% | €7.61 Billion | €47.62 Billion | €20.88 Billion | €13.27 Billion | ▲ +3.2 pp |
| 2022 | 12.7% | €5.68 Billion | €44.64 Billion | €18.42 Billion | €12.74 Billion | ▲ +0.9 pp |
| 2021 | 11.8% | €4.42 Billion | €37.36 Billion | €13.77 Billion | €9.35 Billion | — |